ProKidney Corp. (NASDAQ:PROK) Receives Average Rating of “Hold” from Analysts

Shares of ProKidney Corp. (NASDAQ:PROK) have been given a consensus recommendation of “Hold” by the six research firms that are currently covering the company, MarketBeat reports. Two investment analysts have rated the stock with a sell rating, one has issued a hold rating and three have given a buy rating to the company. The average twelve-month price objective among analysts that have issued ratings on the stock in the last year is $6.25.

Several research analysts recently issued reports on the stock. Zacks Research cut shares of ProKidney from a “strong-buy” rating to a “hold” rating in a report on Monday, August 18th. Weiss Ratings reissued a “sell (d-)” rating on shares of ProKidney in a research note on Wednesday, October 8th.

ProKidney Price Performance

NASDAQ:PROK opened at $2.41 on Monday. The firm has a market cap of $709.21 million, a price-to-earnings ratio of -4.38 and a beta of 1.75. The firm’s fifty day moving average price is $2.81 and its 200 day moving average price is $2.14. ProKidney has a 1-year low of $0.46 and a 1-year high of $7.13.

ProKidney (NASDAQ:PROK) last released its earnings results on Monday, November 10th. The company reported ($0.12) EPS for the quarter, hitting the consensus estimate of ($0.12). The firm had revenue of $0.22 million during the quarter, compared to analyst estimates of $0.04 million. As a group, analysts expect that ProKidney will post -0.57 earnings per share for the current fiscal year.

Insider Transactions at ProKidney

In other ProKidney news, Director Brian Jg Pereira sold 502,136 shares of the stock in a transaction on Thursday, November 13th. The stock was sold at an average price of $2.37, for a total value of $1,190,062.32. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders own 41.49% of the company’s stock.

Hedge Funds Weigh In On ProKidney

Institutional investors and hedge funds have recently made changes to their positions in the stock. Bank of New York Mellon Corp lifted its stake in shares of ProKidney by 4.3% in the first quarter. Bank of New York Mellon Corp now owns 239,673 shares of the company’s stock valued at $210,000 after purchasing an additional 9,903 shares during the period. Zullo Investment Group Inc. purchased a new position in ProKidney in the third quarter valued at about $28,000. AQR Capital Management LLC lifted its position in shares of ProKidney by 106.4% during the 1st quarter. AQR Capital Management LLC now owns 52,570 shares of the company’s stock valued at $46,000 after acquiring an additional 27,098 shares during the period. Deutsche Bank AG lifted its position in shares of ProKidney by 49.4% during the 1st quarter. Deutsche Bank AG now owns 86,337 shares of the company’s stock valued at $76,000 after acquiring an additional 28,546 shares during the period. Finally, Two Sigma Investments LP boosted its stake in shares of ProKidney by 40.4% during the 3rd quarter. Two Sigma Investments LP now owns 99,282 shares of the company’s stock worth $240,000 after acquiring an additional 28,583 shares in the last quarter. 51.59% of the stock is owned by institutional investors and hedge funds.

ProKidney Company Profile

ProKidney Corp., a clinical-stage biotechnology company, provides transformative proprietary cell therapy platform for treating various chronic kidney diseases in the United States. The company's lead product is Renal Autologous Cell Therapy (REACT), an autologous homologous cell admixture, which has completed Phase I clinical trial for REACT in patients with congenital anomalies of the Kidney and Urinary Tract (CAKUT), as well as in Phase III and Phase II clinical trials for the treatment of moderate to severe diabetic kidney disease.